证券代码：601211 证券简称：国泰海通 公告编号：2025-082 国泰海通证券股份有限公司 关于境外全资附属公司债务融资 并由公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: ? 被担保人名称：Haitong Bank,S.A.（以下简称海通银行） 国泰海通证券股份有限公司（以下简称公司或本公司）作为担保人于2025 年7月23日签署《贷款协议》，为境外全资子公司海通银行（以下简称借款人或 被担保人，因公司吸收合并海通证券原因于2025年3月成为本公司境外全资子公 司）等值4.5亿美元银团贷款（以下简称本次银团贷款）提供无条件及不可撤销 的保证担保，担保范围包括贷款本金、利息及交易文件下的其他付款义务（以下 本公告所述担保金额、担保余额及担保总额在计算时未包含浮动利率票据、债券、贷款等利息，浮动 利 率利息需根据实际情况确定。本公告所载金额涉及汇率的，按 2025 年 6 月末美元兑换人民币中间 价、欧元 兑换人民币中间价（1 美元=7.1586 元人民币、1 欧元=8.4024 元人民 ...

国泰海通证券股份有限公司 关于上海谊众药业股份有限公司 股东向特定机构投资者询价转让股份的核查报告 上海证券交易所： 国泰海通证券股份有限公司（以下简称"国泰海通"或"组织券商"）受委 托担任上海凯宝药业股份有限公司（以下简称"上海凯宝"或"转让方"）以向 特定机构投资者询价转让（以下简称"本次询价转让"）方式减持所持有的上海 谊众药业股份有限公司（以下简称"公司"或"上海谊众"）首次公开发行前已 发行股份的组织券商。 经核查，国泰海通就本次询价转让的股东、受让方是否符合《上海证券交易 所科创板上市公司自律监管指引第 4 号——询价转让和配售（2025 年 3 月修订）》 （以下简称"《询价转让和配售指引》"）要求，本次询价转让的询价、转让过 程与结果是否公平、公正，是否符合《询价转让和配售指引》的规定作出如下报 告说明。 序 占总股本比 占所持股份 转让股份来 转让股东名称 转让股份数量（股） 一、本次询价转让概况 （一）本次询价转让出让方 截至 2025 年 7 月 16 日，转让方所持公司股份的数量、比例情况如下： 序号 股东名称 持股数量（股） 持股比例 本次询价转让的转让方为持股 5%以上的股东，非 ...

Group 1 - First Capital's chairman Wu Lishun resigned due to work transfer, with vice chairman Qing Meiping taking over responsibilities, raising concerns about management stability [1] - The transition in leadership may lead to market volatility as investors focus on the company's future strategies and the new leader's direction [1] Group 2 - Guotai Haitong announced a corporate transition and client migration from the original Haitong Securities to Guotai Haitong, effective after the end of trading on August 22 [2] - This move aims to protect investor rights and enhance service quality, potentially impacting market expectations regarding integration efficiency and service improvement [2] Group 3 - Nearly 1,800 funds increased their holdings in Hong Kong stocks, particularly in banking and innovative pharmaceuticals, reflecting a dual expectation for high dividends and high growth [3] - This influx of capital may support stock prices in these sectors and attract more attention to the Hong Kong market, improving overall valuations [3] Group 4 - Public funds reported a profit of 385.1 billion yuan in Q2, significantly up from 251.7 billion yuan in Q1, with broad-based ETFs leading the profitability rankings [4] - The strong performance of passive investment products indicates a growing investor preference for stability, which may influence asset allocation strategies across the industry [4]

Group 1 - The announcement states that from July 23, 2025, the company will add Guotai Haitong Securities Co., Ltd. as a distribution agency for the Baoying North Certificate 50 Component Index Fund [1] - Investors can conduct fund account opening, subscription, and related inquiries through the new distribution agency [1] - The announcement provides contact details for both Baoying Fund Management Co., Ltd. and Guotai Haitong Securities Co., Ltd. for further inquiries [1]

Core Points - The company announced a cash dividend of RMB 0.28 per share (including tax) for A shares [1][2] - The dividend distribution plan was approved at the annual general meeting on May 29, 2025 [1][2] - The record date for the dividend is July 25, 2025, with the ex-dividend date also on July 28, 2025 [1][4] Dividend Distribution Details - The total number of A shares eligible for the dividend is 14,008,645,848 shares after excluding 115,303,000 shares held in the company's repurchase account [2][3] - The calculation for the ex-dividend reference price is based on the formula: (previous closing price - cash dividend) + (subscription price × change in circulating shares) / (1 + change in circulating shares) [2][3] - The actual cash dividend per share remains approximately RMB 0.28 after calculations [2] Tax Implications - Individual shareholders holding shares for over one year are exempt from personal income tax on the dividend, while those holding for one year or less will have tax withheld based on their holding period [5] - For qualified foreign institutional investors (QFII) and renminbi qualified foreign institutional investors (RQFII), a 10% withholding tax applies, resulting in a net dividend of RMB 0.252 per share [6][7] - Hong Kong investors will also face a 10% withholding tax, with the same net dividend of RMB 0.252 per share, and they can apply for tax treaty benefits if applicable [7]

国泰海通证券股份有限公司 关于晋拓科技股份有限公司 首次公开发行限售股上市流通事项的核查意见 限公司首次公开发行股票的批复》（证监许可20221381 号）核准，晋拓科技股 份有限公司（以下简称"公司"）首次公开发行人民币普通股（A 股）6,795.20 万股，并于 2022 年 7 月 25 日在上海证券交易所上市。本次发行证券已于 2022 年 7 月 25 日在上海证券交易所上市。国泰海通证券股份有限公司（以下简称"保 荐机构"或"国泰海通"）担任其持续督导保荐机构，持续督导期间为 2022 年 根据《证券发行上市保荐业务管理办法》《上海证券交易所股票上市规则》 等有关法律、法规要求，国泰海通作为公司首次公开发行股票并上市的持续督导 保荐机构，对公司首次公开发行限售股上市流通事项进行了专项核查，现将本次 核查的情况报告如下： 限公司首次公开发行股票的批复》（证监许可20221381 号）核准，晋拓科技股 份有限公司（以下简称"公司"）首次公开发行人民币普通股（A 股）6,795.20 万 股，并于 2022 年 7 月 25 日在上海证券交易所上市。 本次上市流通的限售股为公司首次公开发行限售股，限售期 ...

Summary of Key Points Core Viewpoint - The company, Shenzhen Minglida Precision Technology Co., Ltd., has decided to postpone certain fundraising investment projects due to market changes and operational needs, reallocating part of the raised funds to a new project in Mexico [1][10]. Group 1: Fundraising Overview - The company issued 10 million convertible bonds with a total face value of 1 billion yuan, netting approximately 991.61 million yuan after deducting issuance costs [1]. - The funds are managed in a dedicated account with strict regulatory oversight, ensuring compliance with relevant laws and regulations [5][11]. Group 2: Investment Projects - The original investment projects included the construction of precision component production bases in Anhui and Jiangxi, and a smart manufacturing project for key components [3]. - The company plans to redirect 45 million yuan (45% of total raised funds) from the postponed projects to a new project for constructing a precision component production base for electric vehicles in Mexico [4][10]. Group 3: Project Postponement Details - The project for the Jiangxi precision component production base will experience delays in reaching its operational status due to various market and operational factors [9][10]. - The postponement does not alter the investment amounts or project content, ensuring no adverse impact on shareholder interests [10][12]. Group 4: Compliance and Oversight - The company has followed necessary procedures for the project postponement, receiving approval from both the board of directors and the supervisory board [11][12]. - The sponsor, Guotai Junan Securities, has confirmed that the postponement complies with regulatory requirements and does not harm the company's or shareholders' interests [12].

根据中银国际证券股份有限公司（以下简称"本公司"）与国泰海通证券股份有限公司签署的相关协议， 自2025年7月18日起，投资者可在国泰海通证券股份有限公司办理本公司旗下交易型开放式指数证券投 资基金的申购、赎回代办业务。现将有关事项公告如下： 一、适用基金及业务范围 ■ 自2025年7月18日起，投资者可通过国泰海通证券股份有限公司办理上述基金份额的申购、赎回等业 务。 1、国泰海通证券股份有限公司 客服电话：95521 网址：www.gtht.com 二、重要提示 上述适用基金的申购、赎回等业务仅适用于处于正常开放期时的基金，基金特殊期间的有关规定详见对 应基金的基金合同和招募说明书等相关法律文件及本公司发布的最新业务公告。 三、投资者可通过以下途径咨询有关详情： 本公告的解释权归中银国际证券股份有限公司所有。 特此公告 网址： www.bocifunds.com 四、风险提示： 投资者在上述证券公司办理本基金的投资事务，具体办理规则及程序请咨询相应申购赎回代理券商的规 定。本公司承诺以诚实信用、勤勉尽责的原则管理和运用基金资产，但不保证基金一定盈利，也不保证 最低收益。基金的过往业绩及其净值高低并不预示其 ...

Core Viewpoint - Hanhigh Group Co., Ltd. is planning to conduct an initial public offering (IPO) of its shares and list on the main board in China, with strategic placement involving its senior management and core employees participating through a dedicated asset management plan [1][2][3]. Approval and Authorization - The board of directors and the shareholders' meeting of Hanhigh Group have approved the application for the IPO of RMB ordinary shares (A shares) [2][3]. - The Shenzhen Stock Exchange and the China Securities Regulatory Commission have reviewed and approved the IPO, confirming that Hanhigh Group meets the issuance and listing conditions [2][3]. Strategic Placement Details - The total number of shares to be publicly issued is 40.01 million, accounting for 10% of the total shares post-issuance, with no existing shareholders selling shares [2][3]. - The initial strategic placement amount is set at 4.001 million shares, which is 10% of the total issuance, with a maximum subscription amount of RMB 75 million [3][4]. Participants in Strategic Placement - The strategic placement will involve a dedicated asset management plan established by Hanhigh Group's senior management and core employees, named "Junxiang 1 Asset Management Plan" [3][5]. - The participants in the Junxiang 1 Asset Management Plan include senior management and core employees of Hanhigh Group, with the total investment amounting to RMB 75 million [5][11]. Compliance and Regulations - The selection criteria for strategic placement investors comply with relevant regulations, ensuring that the number of investors does not exceed 10 and that the placement does not exceed 20% of the total issuance [4][5]. - The lock-up period for shares acquired through the strategic placement is set at 12 months from the date of listing [4][14]. Legal and Regulatory Review - The legal counsel for the main underwriter has confirmed that the selection standards and qualifications for strategic placement investors are in accordance with applicable laws and regulations [15]. - The underwriter has also verified that there are no prohibitive conditions as outlined in the regulations regarding the strategic placement of shares [15].

Core Viewpoint - The event "Rational Investment Accompanying Me - Entering the Listed Company Jilin Aodong" aims to enhance communication between investors and the company, promoting rational, value, and long-term investment concepts [1] Group 1: Company Overview - Jilin Aodong has been recognized as a leading company in the Chinese pharmaceutical industry, ranking among the top 100 pharmaceutical companies in China for 11 consecutive years and awarded as one of the 500 most valuable brands in China [1][2] - The company has transformed from a state-owned deer farm to a publicly listed pharmaceutical company, expanding its business into various fields including traditional Chinese medicine, chemical drugs, health products, and food [2][3] - Jilin Aodong's product portfolio includes well-known products such as Anshen Bnnao Liquid and Xiaoer Chaigui Fever Oral Liquid, supported by a robust product hierarchy aimed at driving performance growth [2][3] Group 2: Business Strategy and Financial Performance - The company operates with a "pharmaceutical + finance + health" multi-wheel drive strategy, leveraging financial investments to enhance its core pharmaceutical business and extend its reach into biopharmaceuticals and internet healthcare [3] - Jilin Aodong holds 628 production approval numbers, with over 300 for both traditional Chinese medicine and chemical drugs, indicating a strong regulatory compliance and product diversity [3] - The company plans to maintain a stable dividend policy, with potential increases as operational performance improves, and is actively working on enhancing sales in its enzyme product line and chain pharmacy profitability [4] Group 3: Investor Engagement and Future Outlook - The event facilitated direct interaction between investors and the company's management, allowing for discussions on dividend policies, product sales, and profitability of chain pharmacies [4] - The company aims to continue its commitment to innovation and responsibility, striving for a more prosperous future while contributing to the development of the Chinese pharmaceutical industry [5]